دورية أكاديمية
أعرض في EDS

Exploring factors shaping antibiotic resistance patterns in Streptococcus pneumoniae during the 2020 COVID-19 pandemic.

التفاصيل البيبلوغرافية
العنوان: Exploring factors shaping antibiotic resistance patterns in Streptococcus pneumoniae during the 2020 COVID-19 pandemic.
المؤلفون: Kovacevic A; Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit, Paris, France.; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France., Smith DRM; Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit, Paris, France.; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France.; Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France.; Health Economics Research Centre, Nuffield Department of Health, University of Oxford, Oxford, United Kingdom., Rahbé E; Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit, Paris, France.; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France., Novelli S; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France., Henriot P; Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France.; PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France., Varon E; Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal de Créteil, Créteil, France., Cohen R; Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d'Etude des Maladies Infectieuses Néonatales et Infantiles (IMRB-GRC GEMINI), Université Paris Est, 94000, Créteil, France.; Groupe de Pathologie Infectieuse Pédiatrique (GPIP), 06200, Nice, France.; Unité Court Séjour, Petits Nourrissons, Service de Néonatologie, Centre Hospitalier, Intercommunal de Créteil, Créteil, France.; Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), 94000, Créteil, France.; Association Française de Pédiatrie Ambulatoire (AFPA), 45000, Orléans, France., Levy C; Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d'Etude des Maladies Infectieuses Néonatales et Infantiles (IMRB-GRC GEMINI), Université Paris Est, 94000, Créteil, France.; Groupe de Pathologie Infectieuse Pédiatrique (GPIP), 06200, Nice, France.; Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), 94000, Créteil, France.; Association Française de Pédiatrie Ambulatoire (AFPA), 45000, Orléans, France., Temime L; Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France.; PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France., Opatowski L; Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit, Paris, France.; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France.
المصدر: ELife [Elife] 2024 Mar 07; Vol. 13. Date of Electronic Publication: 2024 Mar 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, UK : eLife Sciences Publications, Ltd., 2012-
مواضيع طبية MeSH: COVID-19*/epidemiology, Humans ; Streptococcus pneumoniae ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; SARS-CoV-2 ; Pandemics ; Communicable Disease Control
مستخلص: Non-pharmaceutical interventions implemented to block SARS-CoV-2 transmission in early 2020 led to global reductions in the incidence of invasive pneumococcal disease (IPD). By contrast, most European countries reported an increase in antibiotic resistance among invasive Streptococcus pneumoniae isolates from 2019 to 2020, while an increasing number of studies reported stable pneumococcal carriage prevalence over the same period. To disentangle the impacts of the COVID-19 pandemic on pneumococcal epidemiology in the community setting, we propose a mathematical model formalizing simultaneous transmission of SARS-CoV-2 and antibiotic-sensitive and -resistant strains of S. pneumoniae . To test hypotheses underlying these trends five mechanisms were built into the model and examined: (1) a population-wide reduction of antibiotic prescriptions in the community, (2) lockdown effect on pneumococcal transmission, (3) a reduced risk of developing an IPD due to the absence of common respiratory viruses, (4) community azithromycin use in COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains. Among 31 possible pandemic scenarios involving mechanisms individually or in combination, model simulations surprisingly identified only two scenarios that reproduced the reported trends in the general population. They included factors (1), (3), and (4). These scenarios replicated a nearly 50% reduction in annual IPD, and an increase in antibiotic resistance from 20% to 22%, all while maintaining a relatively stable pneumococcal carriage. Exploring further, higher SARS-CoV-2 R 0 values and synergistic within-host virus-bacteria interaction mechanisms could have additionally contributed to the observed antibiotic resistance increase. Our work demonstrates the utility of the mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses on AMR dynamics.
Competing Interests: AK, DS, ER, SN, PH, EV, LT No competing interests declared, RC received consulting fees from Pfizer, Sanofi, MSD, and GSK, including travel grants from Pfizer and payments from Symposium Pfizer, MSD, GSK, and Sanofi, and participated in advisory/data safety monitoring board at Pfizer, Sanofi, MSD, and GSK, CL received travel grants from Pfizer and payments from Symposium Pfizer and MSD, LO received a research grant from Pfizer and Sanofi Pasteur on unrelated topics through her institution
(© 2024, Kovacevic et al.)
References: Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1075-1080. (PMID: 28096340)
Front Cell Infect Microbiol. 2021 Mar 22;11:643326. (PMID: 33828999)
JAMA. 2022 May 24;327(20):2018-2019. (PMID: 35394497)
J Assoc Med Microbiol Infect Dis Can. 2021 Sep 30;6(3):181-197. (PMID: 36337760)
BMC Health Serv Res. 2021 Oct 5;21(1):1048. (PMID: 34610843)
J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82. (PMID: 2154441)
J Infect Dis. 2010 Oct 15;202(8):1287-95. (PMID: 20822454)
J R Soc Interface. 2010 Jun 6;7(47):905-19. (PMID: 19940002)
Biosystems. 2023 Feb;224:104827. (PMID: 36626949)
Int J Mol Sci. 2021 Jun 26;22(13):. (PMID: 34206965)
Antibiotics (Basel). 2023 Feb 02;12(2):. (PMID: 36830218)
Antibiotics (Basel). 2021 Aug 31;10(9):. (PMID: 34572638)
N Engl J Med. 2018 Apr 26;378(17):1583-1592. (PMID: 29694816)
Infect Dis Ther. 2021 Dec;10(4):2575-2591. (PMID: 34529255)
Open Forum Infect Dis. 2021 Apr 13;8(6):ofab185. (PMID: 34183981)
Front Pediatr. 2023 Jul 07;11:1198278. (PMID: 37484765)
BMC Med. 2020 Jul 30;18(1):240. (PMID: 32727547)
Lancet Reg Health West Pac. 2021 Jul;12:100162. (PMID: 34124704)
Lancet Digit Health. 2023 Sep;5(9):e582-e593. (PMID: 37516557)
IJID Reg. 2022 Jul 07;4:88-96. (PMID: 35865274)
Clin Microbiol Infect. 2021 Apr;27(4):520-531. (PMID: 33418017)
Clin Infect Dis. 2023 Feb 8;76(3):e1123-e1128. (PMID: 35579504)
J Infect Dis. 2015 Mar 15;211(6):988-94. (PMID: 25293366)
Clin Infect Dis. 2022 Jan 29;74(2):335-338. (PMID: 33907808)
Evol Appl. 2015 Mar;8(3):273-83. (PMID: 25861385)
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1802-1807. (PMID: 30642967)
EBioMedicine. 2023 Apr;90:104493. (PMID: 36857965)
Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
Proc Biol Sci. 2013 Jun 19;280(1764):20130519. (PMID: 23782877)
Lancet. 2007 Feb 10;369(9560):482-90. (PMID: 17292768)
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa049. (PMID: 34192248)
J Infect. 2020 Dec;81(6):952-960. (PMID: 32987097)
BMC Infect Dis. 2021 Nov 23;21(1):1178. (PMID: 34814857)
PLoS One. 2015 Oct 14;10(10):e0140112. (PMID: 26466142)
PLoS One. 2022 Feb 2;17(2):e0263437. (PMID: 35108332)
BMJ. 2020 May 18;369:m1983. (PMID: 32423901)
Euro Surveill. 2020 Nov;25(45):. (PMID: 33183403)
Lancet Digit Health. 2021 Jun;3(6):e331-e332. (PMID: 34044998)
Lancet. 2021 Mar 20;397(10279):1063-1074. (PMID: 33676597)
J Infect Dis. 2014 Nov 15;210(10):1649-57. (PMID: 24907383)
J Glob Antimicrob Resist. 2021 Sep;26:308-316. (PMID: 34289409)
Lancet Microbe. 2024 Jan;5(1):e34-e42. (PMID: 38048806)
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29063-29068. (PMID: 33139558)
EClinicalMedicine. 2023 Mar;57:101848. (PMID: 36776504)
Nature. 2020 Aug;584(7820):257-261. (PMID: 32512579)
Clin Infect Dis. 2018 Mar 19;66(7):1004-1012. (PMID: 29136126)
Clin Infect Dis. 2021 Mar 1;72(5):e65-e75. (PMID: 33196783)
N Engl J Med. 2020 Nov 12;383(20):1941-1950. (PMID: 33176084)
Microbiol Spectr. 2023 Jun 15;11(3):e0487922. (PMID: 37036377)
JAMA Netw Open. 2021 Sep 1;4(9):e2126114. (PMID: 34550387)
J Antimicrob Chemother. 2022 Apr 27;77(5):1491-1499. (PMID: 35178565)
Aging Clin Exp Res. 2020 Jul;32(7):1189-1194. (PMID: 32458356)
Clin Infect Dis. 1997 Nov;25(5):1113-7. (PMID: 9402367)
J Antimicrob Chemother. 2022 Feb 23;77(3):799-802. (PMID: 34897486)
Infect Dis Now. 2023 Aug;53(5):104720. (PMID: 37196808)
Science. 2020 Jul 10;369(6500):208-211. (PMID: 32404476)
Front Med (Lausanne). 2021 Sep 13;8:719481. (PMID: 34589501)
J Infect Dis. 2008 Apr 15;197(8):1094-102. (PMID: 18419528)
Theor Popul Biol. 2020 Jun;133:150-158. (PMID: 31887315)
Microbiol Spectr. 2023 Feb 14;11(1):e0361522. (PMID: 36645282)
Clin Infect Dis. 2021 Jun 15;72(12):e1021-e1029. (PMID: 33252620)
PLoS Pathog. 2023 Mar 8;19(3):e1011167. (PMID: 36888684)
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. (PMID: 32711058)
Infect Dis (Lond). 2021 Feb;53(2):102-110. (PMID: 33103530)
Lancet Digit Health. 2021 Jun;3(6):e360-e370. (PMID: 34045002)
BMC Infect Dis. 2017 Jun 2;17(1):382. (PMID: 28577533)
Lancet Infect Dis. 2023 Mar;23(3):277-278. (PMID: 36736337)
JAMA Health Forum. 2023 Feb 3;4(2):e225429. (PMID: 36800196)
Nat Ecol Evol. 2019 Mar;3(3):440-449. (PMID: 30742105)
Biosaf Health. 2020 Jun;2(2):57-59. (PMID: 32835209)
BMC Infect Dis. 2017 Dec 13;17(1):765. (PMID: 29237402)
J Clin Med. 2021 Dec 23;11(1):. (PMID: 35011810)
Eur J Public Health. 2023 Dec 9;33(6):987-993. (PMID: 37561411)
J Antimicrob Chemother. 2005 Aug;56(2):365-71. (PMID: 16002421)
Euro Surveill. 2021 Nov;26(46):. (PMID: 34794534)
Elife. 2021 Feb 16;10:. (PMID: 33588991)
BMJ. 2022 Jan 12;376:e067519. (PMID: 35022215)
PLoS Med. 2023 Jun 5;20(6):e1004240. (PMID: 37276186)
J Travel Med. 2020 Mar 13;27(2):. (PMID: 32052846)
mBio. 2012 Sep 25;3(5):. (PMID: 23015738)
Lancet Infect Dis. 2022 May;22(5):657-667. (PMID: 35247320)
Clin Microbiol Infect. 2021 Jan;27(1):83-88. (PMID: 32745596)
J R Soc Interface. 2013 Jul 03;10(86):20130233. (PMID: 23825111)
Clin Microbiol Infect. 2021 Feb 16;:. (PMID: 33601010)
Ann Intern Med. 2020 May 05;172(9):577-582. (PMID: 32150748)
J Infect Dis. 2012 Oct 1;206(7):1020-9. (PMID: 22829650)
Antibiotics (Basel). 2021 May 17;10(5):. (PMID: 34067546)
Epidemiol Infect. 2004 Jun;132(3):433-41. (PMID: 15188713)
FASEB J. 2010 Jun;24(6):1789-98. (PMID: 20097876)
J Infect Dis. 2021 Mar 29;223(6):1019-1028. (PMID: 33507308)
J Infect Dis. 2021 Sep 17;224(6):949-955. (PMID: 33856455)
Antibiotics (Basel). 2022 Aug 05;11(8):. (PMID: 36009932)
JAMA Netw Open. 2020 Sep 1;3(9):e2020498. (PMID: 32902653)
Front Microbiol. 2023 Oct 12;14:1280026. (PMID: 37901822)
Front Cell Infect Microbiol. 2022 Jan 17;11:825427. (PMID: 35111700)
Antibiotics (Basel). 2022 May 11;11(5):. (PMID: 35625287)
Life (Basel). 2021 Mar 10;11(3):. (PMID: 33801799)
Z Gesundh Wiss. 2022;30(11):2719-2727. (PMID: 34036037)
Epidemics. 2009 Mar;1(1):2-13. (PMID: 21352747)
JAMA Netw Open. 2022 Jun 1;5(6):e2218959. (PMID: 35763298)
Open Forum Infect Dis. 2023 Jul 20;10(8):ofad365. (PMID: 37559754)
PLoS Comput Biol. 2023 Oct 27;19(10):e1011564. (PMID: 37889910)
Int J Infect Dis. 2021 Mar;104:708-710. (PMID: 33548553)
معلومات مُعتمدة: ANR-10-LABX-62 IBEID Agence Nationale de la Recherche; AAP Covid-19 2020 Université Paris-Saclay; SPHINX-17-CE36-0008-01 Agence Nationale de la Recherche; MODCOV Grant 106059 Fondation de France
فهرسة مساهمة: Keywords: COVID-19 pandemic; SARS-CoV-2; Streptococcus pneumoniae; antibiotic resistance; ecology; epidemiology; global health; invasive pneumococcal disease; virus-bacteria interactions
المشرفين على المادة: 0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240307 Date Completed: 20240308 Latest Revision: 20240310
رمز التحديث: 20240310
مُعرف محوري في PubMed: PMC10923560
DOI: 10.7554/eLife.85701
PMID: 38451256
قاعدة البيانات: MEDLINE
الوصف
تدمد:2050-084X
DOI:10.7554/eLife.85701